Yes, Tremfya (guselkumab) is a biologic medication. Specifically, it is a fully human monoclonal antibody, one of the most targeted types of biologic drugs available. It is manufactured using living cells and recombinant DNA technology, which is what distinguishes biologics from conventional drugs made through chemical synthesis.
What Makes Tremfya a Biologic
Biologics are medications derived from living organisms rather than assembled from chemicals in a lab. Tremfya is produced in Chinese Hamster Ovary (CHO) cells, a common cell line used to grow complex proteins that can’t be replicated through standard manufacturing. The result is a large, precisely shaped protein molecule, classified as a fully human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody.
This matters because the size and complexity of biologic drugs affect how they’re delivered. Unlike small-molecule pills that survive the digestive system, biologics like Tremfya are proteins that would break down in your stomach. That’s why Tremfya is given by injection or, for certain conditions, intravenous infusion.
How Tremfya Works in the Body
Tremfya targets a very specific piece of the immune system: a signaling protein called interleukin-23 (IL-23). IL-23 is one of the chemical messengers that drives inflammation in conditions like psoriasis and inflammatory bowel disease. Tremfya locks onto a particular part of IL-23 called the p19 subunit, preventing it from attaching to receptors on immune cells. When that connection is blocked, the chain reaction of inflammation that causes skin plaques, joint pain, or intestinal damage slows down significantly.
What makes this approach different from older biologics is its precision. Some earlier drugs blocked both IL-23 and a related molecule called IL-12. Tremfya leaves IL-12 alone, targeting only the IL-23 pathway. This narrower focus is thought to reduce unnecessary suppression of the immune system while still controlling the disease.
What Tremfya Is Approved to Treat
The FDA has approved Tremfya for four conditions:
- Plaque psoriasis: the most common form of psoriasis, causing raised, scaly patches on the skin
- Psoriatic arthritis: joint inflammation that occurs alongside or independently of skin psoriasis
- Ulcerative colitis: chronic inflammation of the large intestine
- Crohn’s disease: inflammation that can affect any part of the digestive tract
For psoriasis and psoriatic arthritis, treatment involves a 100 mg injection under the skin at the start, again at week 4, and then every 8 weeks. For ulcerative colitis and Crohn’s disease, treatment begins with intravenous infusions during the first few months before transitioning to self-administered injections for ongoing maintenance.
How Effective Tremfya Is for Psoriasis
Clinical trial data for Tremfya in plaque psoriasis is strong. In the VOYAGE 2 trial, 70% of patients achieved 90% or greater skin clearance by week 16, compared to just 2.4% on placebo. More than 84% reached a rating of “clear” or “minimal” skin. Tremfya also outperformed adalimumab (a widely used older biologic) at both week 16 and week 24 across multiple measures of skin clearance, with statistically significant differences.
These numbers represent a meaningful step up from earlier generations of biologics. For many patients, near-complete clearance of psoriasis plaques is a realistic outcome rather than an aspirational one.
Screening and Safety Considerations
Because Tremfya suppresses part of the immune system, your doctor will run several tests before starting treatment. Tuberculosis screening is required, typically through a skin test or blood test. Hepatitis B and hepatitis C screening are also standard. You won’t be started on Tremfya if you have an active serious infection, untreated tuberculosis, or unmanaged hepatitis B, though treatment can begin once those issues are addressed.
This pre-treatment screening is common across biologics, not unique to Tremfya. The underlying logic is straightforward: any drug that dials down immune activity could make it harder for your body to fight certain infections, so your doctor needs to know your baseline status before you begin.
How Tremfya Compares to Other Biologics
Tremfya belongs to a class of biologics called IL-23 inhibitors, which also includes risankizumab (Skyrizi) and tildrakizumab (Ilumya). These drugs all target the p19 subunit of IL-23 and share a similar dosing convenience, with injections spaced weeks apart rather than daily or weekly.
Older biologics for psoriasis and psoriatic arthritis include TNF inhibitors (like adalimumab and etanercept) and IL-17 inhibitors (like secukinumab). IL-23 inhibitors are generally considered a newer generation, offering high efficacy with less frequent dosing. The every-8-week maintenance schedule for psoriasis is one of the more convenient among injectable biologics, which is a practical factor when choosing a long-term treatment.
The fact that Tremfya is a biologic also affects cost. Biologics are among the most expensive medications on the market because of their complex manufacturing process. Insurance coverage, copay assistance programs, and specialty pharmacy requirements are all part of the landscape when starting any biologic, including Tremfya.